Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 156,005
  • Shares Outstanding, K 27,858
  • Annual Sales, $ 34,050 K
  • Annual Income, $ -131,000 K
  • 60-Month Beta 1.61
  • Price/Sales 4.43
  • Price/Cash Flow N/A
  • Price/Book 3.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.95
  • Number of Estimates 5
  • High Estimate -0.88
  • Low Estimate -1.00
  • Prior Year -1.06
  • Growth Rate Est. (year over year) +10.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.65 +53.42%
on 11/08/19
5.71 -1.93%
on 11/14/19
+1.70 (+43.59%)
since 10/14/19
3-Month
3.35 +67.16%
on 10/10/19
7.78 -28.02%
on 09/23/19
-0.46 (-7.59%)
since 08/14/19
52-Week
3.35 +67.16%
on 10/10/19
12.57 -55.45%
on 03/04/19
-5.26 (-48.43%)
since 11/14/18

Most Recent Stories

More News
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the option to purchase an aggregate of 14,500...

ADMS : 5.60 (unch)
Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Lags Revenue Estimates

Adamas (ADMS) delivered earnings and revenue surprises of -10.00% and -2.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMS : 5.60 (unch)
Adamas: 3Q Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Thursday reported a loss of $27.6 million in its third quarter.

ADMS : 5.60 (unch)
What's in the Offing for Humana's (HUM) Earnings in Q3?

Humana's (HUM) third-quarter results are likely to reflect rise in expenses and a negative impact from seasonality on its bottom line.

ADMS : 5.60 (unch)
HUM : 318.00 (-0.28%)
ABC : 86.13 (+0.05%)
ACB : 3.29 (-7.32%)
Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas' management...

ADMS : 5.60 (unch)
Adamas Pharmaceu Set to Possibly Rebound After Yesterday's Selloff of 4.53%

Adamas Pharmaceu (NASDAQ:ADMS) traded in a range yesterday that spanned from a low of $3.52 to a high of $3.80. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $3.80...

ADMS : 5.60 (unch)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 44,375...

ADMS : 5.60 (unch)
Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane,...

ADMS : 5.60 (unch)
19.3% Return Seen to Date on SmarTrend Adamas Pharmaceu Call (ADMS)

SmarTrend identified an Uptrend for Adamas Pharmaceu (NASDAQ:ADMS) on June 25th, 2019 at $5.91. In approximately 3 months, Adamas Pharmaceu has returned 19.29% as of today's recent price of $7.05.

ADMS : 5.60 (unch)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Ardelyx Inc (ARDX , ADMS , RARE , MGNX , FLXN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ADMS : 5.60 (unch)
ARDX : 6.15 (+1.32%)
RARE : 36.78 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ADMS with:

Business Summary

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone...

See More

Key Turning Points

2nd Resistance Point 5.90
1st Resistance Point 5.75
Last Price 5.60
1st Support Level 5.38
2nd Support Level 5.16

See More

52-Week High 12.57
Fibonacci 61.8% 9.05
Fibonacci 50% 7.96
Fibonacci 38.2% 6.87
Last Price 5.60
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar